Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

Blood (2023) 141 (3): 219–230.

https://doi.org/10.1182/blood.2022015526

Published: 2023

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Ciltacabtagene Autoleucel (Cilta-cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1-3 Prior Lines of Therapy: Updated Results from CARTITUDE-2

Blood (2021) 138 (Supplement 1): 3866.

https://doi.org/10.1182/blood-2021-146072

Published: 2021

Journal Articles

Anakinra Targeting Cytokine Release Syndrome Associated with Chimeric Antigen Receptor T-Cell Therapies

Sandy W. Wong, Shambavi Richard, Yi Lin, Deepu Madduri, Carolyn C. Jackson, Enrique Zudaire, Vadim Romanov, Michael Trigg, Martin Vogel, Ashraf Garrett, Lisa Hullinger, Tonia Nesheiwat, Thomas Martin, Sundar Jagannath

Blood (2021) 138 (Supplement 1): 2812.

https://doi.org/10.1182/blood-2021-150592

Published: 2021

Journal Articles

CARTITUDE-2: Efficacy and Safety of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell Therapy, in Patients with Multiple Myeloma and Early Relapse after Initial Therapy

Blood (2021) 138 (Supplement 1): 2910.

https://doi.org/10.1182/blood-2021-146074

Published: 2021

Journal Articles

LocoMMotion: A Prospective, Non-Interventional, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma Who Received ≥3 Prior Lines of Therapy

Blood (2021) 138 (Supplement 1): 3057.

https://doi.org/10.1182/blood-2021-146188

Published: 2021

Journal Articles

Meta-Analysis of Ciltacabtagene Autoleucel Versus Physician's Choice in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 1676.

https://doi.org/10.1182/blood-2021-146177

Published: 2021

Journal Articles

Circulating Tumor Cells As a Surrogate Marker for Bone Marrow Minimal Residual Disease and an Adverse Prognostic Factor for Patients with Multiple Myelom

Stefanie Huhn, PhD, Mathias Hänel, MD, Thomas Hielscher, PhD, Uta Bertsch, MD, Hans Jürgen Salwender, Norma Peter, MD, Hartmut Kirchner, Helga Bernhard, MD, Martin Vogel, Ralf Angermund, Martin Goerner, MD, Katja C. Weisel, Jan Duering, Igor W Blau, Niels Weinhold, PhD, Hartmut Goldschmidt, MD

Blood (2017) 130 (Supplement 1): 4359.

https://doi.org/10.1182/blood.V130.Suppl_1.4359.4359

Published: 2017

Journal Articles

Bortezomib Consolidation Following Autologous Transplant Equalizes the Outcome for Older Patients with Less Intensive Pretreatment Compared to Younger Patients with Newly Diagnosed Multiple Myeloma

Blood (2016) 128 (22): 516.

https://doi.org/10.1182/blood.V128.22.516.516

Published: 2016

Journal Articles

Bortezomib and Low-Dose Dexamethasone with or without Continuous Low-Dose Oral Cyclophosphamide for Primary Refractory or Relapsed Multiple Myeloma: Final Results of a National Multicenter Randomized Controlled Phase III Study

Martin Kropff, MD, Martin Vogel, MD PhD, Andrea Kreter, Dipl. Stat., Rudolf Schlag, Lothar Müller, MD, Rudolf Weide, MD, Wolfgang Knauf, MD PhD, Thomas Decker, MD, Heinrich Fiechtner, PhD, Georgi Kojouharoff, MD, Stephan Kremers, MD, Wolfgang E Berdel, MD

Blood (2014) 124 (21): 3470.

https://doi.org/10.1182/blood.V124.21.3470.3470

Published: 2014

Journal Articles

Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease

Christian Hoffmann, Holger Schmid, Markus Müller, Christian Teutsch, Jan van Lunzen, Stefan Esser, Timo Wolf, Christoph Wyen, Michael Sabranski, Heinz-August Horst, Stefan Reuter, Martin Vogel, Hans Jäger, Johannes Bogner, Keikawus Arasteh

Blood (2011) 118 (13): 3499–3503.

https://doi.org/10.1182/blood-2011-02-333633

Published: 2011

NARROW

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

Efficacy and Safety of Ciltacabtagene Autoleucel (Cilta-cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1-3 Prior Lines of Therapy: Updated Results from CARTITUDE-2

Anakinra Targeting Cytokine Release Syndrome Associated with Chimeric Antigen Receptor T-Cell Therapies

CARTITUDE-2: Efficacy and Safety of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell Therapy, in Patients with Multiple Myeloma and Early Relapse after Initial Therapy

LocoMMotion: A Prospective, Non-Interventional, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma Who Received ≥3 Prior Lines of Therapy

Meta-Analysis of Ciltacabtagene Autoleucel Versus Physician's Choice in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Circulating Tumor Cells As a Surrogate Marker for Bone Marrow Minimal Residual Disease and an Adverse Prognostic Factor for Patients with Multiple Myelom

Bortezomib Consolidation Following Autologous Transplant Equalizes the Outcome for Older Patients with Less Intensive Pretreatment Compared to Younger Patients with Newly Diagnosed Multiple Myeloma

Bortezomib and Low-Dose Dexamethasone with or without Continuous Low-Dose Oral Cyclophosphamide for Primary Refractory or Relapsed Multiple Myeloma: Final Results of a National Multicenter Randomized Controlled Phase III Study

Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only